Dr. Reddy’s hit with RUB 9.27m Russian tax penalty

Dr. Reddy’s Laboratories Limited reports that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories LLC in Russia, has received a final penalty decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia.

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited reports that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories LLC in Russia, has received a final penalty decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia. The decision relates to Value Added Tax on marketing services reclassified as taxable services.

The Russian tax authority set the penalty at RUB 9.27 million (approximately INR 11.40 million), reduced from an originally quantified amount of RUB 20.09 million (approximately INR 24.50 million). The company states that this penalty has no material impact on its financials, operations or other activities.

Key Figures

Final penalty amount: RUB 9.27 million Final penalty in INR: INR 11.40 million Original quantified penalty: RUB 20.09 million +3 more

6 metrics

Final penalty amount RUB 9.27 million VAT-related penalty set by Russian tax authority

Final penalty in INR INR 11.40 million Approximate value of RUB 9.27 million penalty

Original quantified penalty RUB 20.09 million Initial amount quantified by Russian tax authority

Original penalty in INR INR 24.50 million Approximate value of original RUB 20.09 million

Date of final decision April 13, 2026 Date subsidiary received final penalty decision

Disclosure date April 14, 2026 Date Dr. Reddy’s informed stock exchanges

Key Terms

Value Added Tax (VAT), final penalty decision, step-down wholly-owned subsidiary, Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, +1 more

5 terms

Value Added Tax (VAT) financial

"Levy of Value Added Tax (VAT) upon re-classification of marketing services"

A value added tax (VAT) is a consumption tax added to the sale price of goods and services and collected by businesses on behalf of the government. Think of it like a toll charged at each step of making and selling a product: businesses collect the tax from customers, pass it on to the tax authority, and may offset what they paid on purchases. VAT matters to investors because it affects a company’s pricing, cash flow, reported sales and expenses, profit margins, and compliance costs, and can influence competitiveness in different markets.

final penalty decision regulatory

"has received final penalty decision on April 13, 2026, from the ‘Interdistrict Inspectorate"

step-down wholly-owned subsidiary financial

"Dr. Reddy’s Laboratories LLC, Russia, a step-down wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited"

Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory

"Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

Interdistrict Inspectorate of the Federal Tax Service of Russia regulatory

"from the ‘Interdistrict Inspectorate of the Federal Tax Service of Russia’."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What tax penalty did Dr. Reddy’s Laboratories LLC, Russia receive in this 6-K filing for RDY?

Dr. Reddy’s Laboratories LLC, Russia received a final tax penalty of RUB 9.27 million. This arose after Russian authorities reclassified certain marketing services as taxable for Value Added Tax, leading to an assessed VAT-related penalty for the subsidiary.

How does the final Russian tax penalty for Dr. Reddy’s (RDY) compare with the original amount?

The final Russian tax penalty was set at RUB 9.27 million versus an original quantified amount of RUB 20.09 million. This represents a significant reduction from the initial assessment made by the Russian tax authority on the subsidiary.

What is the financial impact of the Russian VAT penalty on Dr. Reddy’s Laboratories Limited (RDY)?

Dr. Reddy’s states that the RUB 9.27 million (about INR 11.40 million) penalty has no material impact on its financials. The company also notes no material impact on operations or other activities arising from this Russian tax authority decision.

Which authority imposed the VAT-related penalty on Dr. Reddy’s subsidiary in Russia?

The penalty was imposed by the Interdistrict Inspectorate of the Federal Tax Service of Russia. This tax authority issued a final penalty decision concerning Value Added Tax on reclassified marketing services provided by Dr. Reddy’s Laboratories LLC, Russia.

When did Dr. Reddy’s (RDY) receive the final Russian tax penalty decision mentioned in the 6-K?

Dr. Reddy’s Laboratories LLC, Russia received the final penalty decision on April 13, 2026. The company then reported this development on April 14, 2026, through its disclosure to Indian and international stock exchanges.

What triggered the Russian VAT penalty for Dr. Reddy’s subsidiary according to the filing?

The penalty was triggered by the levy of Value Added Tax after Russian authorities reclassified certain marketing services as taxable services. This reclassification by the Interdistrict Inspectorate of the Federal Tax Service of Russia led to the assessed VAT-related penalty.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 06:24 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

April, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                            Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                             No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated April 14, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: April 14, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:      + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

April 14, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Ref:        Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In furtherance to our disclosure dated January 24, 2026, this is to inform that Dr. Reddy’s Laboratories LLC, Russia, a step-down wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited has received final penalty decision on April 13, 2026, from the ‘Interdistrict Inspectorate of the Federal Tax Service of Russia’. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:

S. No.	Name of the authority	:	The Interdistrict Inspectorate of the Federal Tax Service of Russia. (Tax Authority)
1	Nature and details of the action(s) taken, or order(s) passed	:	Dr. Reddy’s Laboratories LLC, Russia, a step-down wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited received a final penalty decision from the Tax Authority.
2	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	:	April 13, 2026
3	Details of the violation(s)/ contravention(s) committed or alleged to be committed	:	Levy of Value Added Tax (VAT) upon re-classification of marketing services as a taxable services by the Tax Authority.
4	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	:	The Tax Authority has quantified a penalty of RUB 9.27 million (INR 11.40 million) as against the original quantified amount of RUB 20.09 million (INR 24.50 million) Based on our evaluation, the above stated penalty amount has no material impact on the financials, operations, or other activities of the Company

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 35.9 KB